Search - tctmd.com

Displaying 1 - 20 of 961

Sort: Relevancy | Date

Clinician EHR Alerts Lead to Speedier Evaluation, Treatment of Valve Disease

News Conference News ACC 2026

Clinician EHR Alerts Lead to Speedier Evaluation, Treatment of Valve Disease

April 01, 2026

Transcatheter ViV a Solid Option for Failed Mitral Bioprostheses: SURViV

News Conference News ACC 2026

Transcatheter ViV a Solid Option for Failed Mitral Bioprostheses: SURViV

March 30, 2026

Impella Support in High-Risk PCI Doesn’t Help, Might Harm: CHIP-BCIS3

News Conference News ACC 2026

Impella Support in High-Risk PCI Doesn’t Help, Might Harm: CHIP-BCIS3

Yael L. Maxwell

March 29, 2026

US Societies Lay Out Requirements for Transcatheter Tricuspid Valve Procedures

News Daily News

US Societies Lay Out Requirements for Transcatheter Tricuspid Valve Procedures

Michael O'Riordan

March 27, 2026

FDA Approves JenaValve’s Trilogy for Aortic Regurgitation

News Daily News

FDA Approves JenaValve’s Trilogy for Aortic Regurgitation

Michael O'Riordan

March 23, 2026

Should Moderate FMR Should Be Treated With M-TEER? Experts Duke It Out

News Conference News THT 2026

Should Moderate FMR Be Treated With M-TEER? Experts Duke It Out

March 06, 2026

NT-proBNP Provides Info on Who Will Fare Well After Tricuspid TEER

News Conference News THT 2026

NT-proBNP Provides Info on Who Will Fare Well After Tricuspid TEER

March 04, 2026

Surgical Mitral Valve Repair Outcomes ‘Excellent’ at 2 Years: CTSN

News Daily News

Surgical Mitral Valve Repair Outcomes ‘Excellent’ at 2 Years: CTSN

Yael L. Maxwell

February 26, 2026

THT 2026: What to Expect in Boston

News Conference News THT 2026

THT 2026: What to Expect in Boston

February 23, 2026

Higher Reintervention Risk With TAVI Emerges at 6 to 7 Years in Evolut Low Risk Trial

News Daily News

Higher Reintervention Risk With TAVI Emerges at 6 to 7 Years in Evolut Low Risk Trial

Michael O'Riordan

February 19, 2026

Meta-analysis Teases Out What Drives Success in M-TEER

News Daily News

Meta-analysis Teases Out What Drives Success in M-TEER

February 10, 2026

Worse TAVI and M-TEER Outcomes Seen With Low-Volume Operators

News Daily News

Worse TAVI and M-TEER Outcomes Seen With Low-Volume Operators

Michael O'Riordan

January 22, 2026

Revathy Sampath-Kumar, MD

News Featured Fellow

Revathy Sampath-Kumar, MD

Yael L. Maxwell

January 13, 2026

Year in Review: Structural Heart in 2025 Features EARLY TAVR, Tricuspid Nuance, Mitral Gains

News Daily News

Year in Review: Structural Heart in 2025 Features EARLY TAVR, Tricuspid Nuance, Mitral Gains

December 31, 2025

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

FDA Approves Sapien M3 for Transseptal Mitral Valve Replacement

News Daily News

FDA Approves Sapien M3 for Transseptal Mitral Valve Replacement

Michael O'Riordan

December 23, 2025

Largest AI-Echo Model Shows Promise for Increasing Workflow Efficiency

News Daily News

Largest AI-Echo Model Shows Promise for Increasing Workflow Efficiency

Yael L. Maxwell

November 17, 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

News Conference News TCT 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

October 27, 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

News Conference News TCT 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

Yael L. Maxwell

October 27, 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

News Conference News TCT 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

October 27, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.